{"Standard": [0], "first-line": [1], "chemotherapy": [2, 16, 115, 265, 274], "for": [3, 196, 246], "endometrial": [4, 50, 257], "cancer": [5, 51], "is": [6], "paclitaxel": [7, 66], "plus": [8, 67], "carboplatin.": [9, 68], "The": [10, 69, 93, 127], "benefit": [11], "of": [12, 22, 71, 147, 152, 175, 261], "adding": [13], "pembrolizumab": [14, 58, 72, 186, 226, 247, 262], "to": [15, 56, 86, 101, 141, 206, 238, 263], "remains": [17], "unclear.": [18], "Download": [19], "a": [20, 53, 209], "PDF": [21], "the": [23, 119, 134, 145, 157, 166, 170, 179, 185, 191, 216, 259, 278], "Research": [24], "Summary.": [25], "In": [26, 169, 215, 251], "this": [27], "double-blind,": [28], "placebo-controlled,": [29], "randomized,": [30], "phase": [31], "3": [32, 81], "trial,": [33], "we": [34], "assigned": [35], "816": [36], "patients": [37, 94, 252], "with": [38, 62, 65, 225, 230, 253, 273], "measurable": [39], "disease": [40], "(stage": [41], "III": [42], "or": [43, 45, 48, 59, 73, 108, 154, 198, 255], "IVA)": [44], "stage": [46], "IVB": [47], "recurrent": [49, 256], "in": [52, 77, 133, 156, 165, 178, 184, 190, 212, 267, 292], "1:1": [54], "ratio": [55, 195], "receive": [57], "placebo": [60, 74, 192, 231], "along": [61], "combination": [63, 249], "therapy": [64], "administration": [70], "was": [75, 116, 122, 130, 222], "planned": [76], "6": [78, 91], "cycles": [79, 89], "every": [80, 90], "weeks,": [82], "followed": [83], "by": [84, 277], "up": [85], "14": [87], "maintenance": [88], "weeks.": [92], "were": [95, 139, 182, 243], "stratified": [96], "into": [97], "two": [98, 135], "cohorts": [99], "according": [100], "whether": [102], "they": [103], "had": [104], "mismatch": [105, 109], "repair\u2013deficient": [106], "(dMMR)": [107], "repair\u2013proficient": [110], "(pMMR)": [111], "disease.": [112], "Previous": [113], "adjuvant": [114], "permitted": [117], "if": [118], "treatment-free": [120], "interval": [121, 203], "at": [123, 148, 161], "least": [124, 149, 162], "12": [125], "months.": [126], "primary": [128], "outcome": [129], "progression-free": [131, 176, 220, 270], "survival": [132, 177, 221, 271], "cohorts.": [136], "Interim": [137], "analyses": [138], "scheduled": [140], "be": [142], "triggered": [143], "after": [144], "occurrence": [146], "84": [150], "events": [151, 164, 242], "death": [153], "progression": [155, 197], "dMMR": [158, 180], "cohort": [159, 181], "and": [160, 188, 227, 248, 282], "196": [163], "pMMR": [167, 217], "cohort.": [168], "12-month": [171], "analysis,": [172], "Kaplan\u2013Meier": [173], "estimates": [174], "74%": [183], "group": [187, 193], "38%": [189], "(hazard": [194, 232], "death,": [199], "0.30;": [200], "95%": [201, 235], "confidence": [202], "[CI],": [204], "0.19": [205], "0.48;": [207], "P<0.001),": [208], "70%": [210], "difference": [211], "relative": [213], "risk.": [214], "cohort,": [218], "median": [219], "13.1": [223], "months": [224, 229], "8.7": [228], "ratio,": [233], "0.54;": [234], "CI,": [236], "0.41": [237], "0.71;": [239], "P<0.001).": [240], "Adverse": [241], "as": [244], "expected": [245], "chemotherapy.": [250], "advanced": [254], "cancer,": [258], "addition": [260], "standard": [264], "resulted": [266], "significantly": [268], "longer": [269], "than": [272], "alone.": [275], "(Funded": [276], "National": [279], "Cancer": [280, 295], "Institute": [281], "others;": [283], "NRG-GY018": [284], "ClinicalTrials.gov": [285], "number,": [286], "NCT03914612.)": [287], "QUICK": [288], "TAKE": [289], "VIDEO": [290], "SUMMARYPembrolizumab": [291], "Advanced": [293], "Endometrial": [294], "02:16": [296]}